{"id":"budesonide-extrafine-pmdi","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Oral thrush"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Upper respiratory tract infection"},{"rate":"5-10%","effect":"Bronchitis"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to glucocorticoid receptors, which then decrease the production of pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines. This leads to a reduction in airway inflammation and improved symptoms in patients with asthma and COPD.","oneSentence":"Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:22:56.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of COPD"}]},"trialDetails":[{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT01070524","phase":"PHASE2","title":"Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-01","conditions":"Asthma","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide extrafine pMDI is a glucocorticoid receptor agonist used to treat conditions such as COPD and asthma. It is a small molecule medication that combines budesonide with formoterol fumarate in a specific ratio.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}